Targeted Therapy for Hepatocellular Carcinoma: Co-Delivery of Sorafenib and Curcumin Using Lactosylated pH-Responsive Nanoparticles

References

• HartkeJ, JohnsonM, GhabrilM. The diagnosis and treatment of hepatocellular carcinoma. Semin Diagn Pathol. 2017;34(2):153–159. doi:10.1053/j.semdp.2016.12.01128108047
   PubMed Web of Science ®Google Scholar
• GrandhiMS, KimAK, Ronnekleiv-KellySM, KamelIR, GhasebehMA, PawlikTM. Hepatocellular carcinoma: from diagnosis to treatment. Surg Oncol. 2016;25(2):74–85. doi:10.1016/j.suronc.2016.03.00227312032
   PubMed Web of Science ®Google Scholar
• KalyanA, NimeiriH, KulikL. Systemic therapy of hepatocellular carcinoma: current and promising. Clin Liver Dis. 2015;19(2):421–432. doi:10.1016/j.cld.2015.01.00925921671
   PubMed Web of Science ®Google Scholar
• ChongDQ, TanIB, ChooSP, TohHC. The evolving landscape of therapeutic drug development for hepatocellular carcinoma. Contemp Clin Trials. 2013;36(2):605–615. doi:10.1016/j.cct.2013.03.01323591326
   PubMed Web of Science ®Google Scholar
• ZhuAX. Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives. Semin Oncol. 2012;39(4):493–502. doi:10.1053/j.seminoncol.2012.05.01422846866
   PubMed Web of Science ®Google Scholar
• Méndez-BlancoC, FondevilaF, García-PalomoA, González-GallegoJ, MaurizJL. Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors. Exp Mol Med. 2018;50(10):134. doi:10.1038/s12276-018-0159-130315182
   PubMed Web of Science ®Google Scholar
• WangC, SuL, WuC, WuJ, ZhuC, YuanG. RGD peptide targeted lipid-coated nanoparticles for combinatorial delivery of sorafenib and quercetin against hepatocellular carcinoma. Drug Dev Ind Pharm. 2016;42(12):1938–1944. doi:10.1080/03639045.2016.118543527142812
   PubMed Web of Science ®Google Scholar
• CaoC, WangQ, LiuY. Lung cancer combination therapy: doxorubicin and β-elemene co-loaded, pH-sensitive nanostructured lipid carriers. Drug Des Devel Ther. 2019;13:1087–1098. doi:10.2147/DDDT.S198003
   PubMed Web of Science ®Google Scholar
• HanY, ZhangY, LiD, ChenY, SunJ, KongF. Transferrin-modified nanostructured lipid carriers as multifunctional nanomedicine for codelivery of DNA and doxorubicin. Int J Nanomedicine. 2014;9:4107–4116. doi:10.2147/IJN.S6777025187713
   PubMed Web of Science ®Google Scholar
• ElnaggarMH, AbushoukAI, HassanAHE, et al. Nanomedicine as a putative approach for active targeting of hepatocellular carcinoma. Semin Cancer Biol. 2019;S1044-579X(19)30225–1.
   Web of Science ®Google Scholar
• YuW, LiuC, LiuY, ZhangN, XuW. Mannan-modified solid lipid nanoparticles for targeted gene delivery to alveolar macrophages. Pharm Res. 2010;27(8):1584–1596. doi:10.1007/s11095-010-0149-z20422265
   PubMed Web of Science ®Google Scholar
• YuW, ZhangN, LiC. Saccharide modified pharmaceutical nanocarriers for targeted drug and gene delivery. Curr Pharm Des. 2009;15(32):3826–3836. doi:10.2174/13816120978964954719925431
   PubMed Web of Science ®Google Scholar
• ThaoLQ, LeeC, KimB, et al. Doxorubicin and paclitaxel co-bound lactosylated albumin nanoparticles having targetability to hepatocellular carcinoma. Colloids Surf B Biointerfaces. 2017;152:183–191. doi:10.1016/j.colsurfb.2017.01.01728110040
   PubMed Web of Science ®Google Scholar
• Teran-SaavedraNG, Sarabia-SainzJA, Silva-CampaE, et al. Lactosylated albumin nanoparticles: potential drug nanovehicles with selective targeting toward an in vitro model of hepatocellular carcinoma. Molecules. 2019;24:7. doi:10.3390/molecules24071382
   Web of Science ®Google Scholar
• CuiT, ZhangS, SunH. Co-delivery of doxorubicin and pH-sensitive curcumin prodrug by transferrin-targeted nanoparticles for breast cancer treatment. Oncol Rep. 2017;37(2):1253–1260. doi:10.3892/or.2017.534528075466
   PubMed Web of Science ®Google Scholar
• TanS, WangG. Redox-responsive and pH-sensitive nanoparticles enhanced stability and anticancer ability of erlotinib to treat lung cancer in vivo. Drug Des Devel Ther. 2017;11:3519–3529. doi:10.2147/DDDT
   PubMed Web of Science ®Google Scholar
• LiS, WangL, LiN, LiuY, SuH. Combination lung cancer chemotherapy: design of a pH-sensitive transferrin-PEG-Hz-lipid conjugate for the co-delivery of docetaxel and baicalin. Biomed Pharmacother. 2017;95:548–555. doi:10.1016/j.biopha.2017.08.09028869892
   PubMed Web of Science ®Google Scholar
• ZhangR, RuY, GaoY, LiJ, MaoS. Layer-by-layer nanoparticles co-loading gemcitabine and platinum (IV) prodrugs for synergistic combination therapy of lung cancer. Drug Des Devel Ther. 2017;11:2631–2642. doi:10.2147/DDDT
   PubMed Web of Science ®Google Scholar
• KhanMW, ZhaoP, KhanA, et al. Synergism of cisplatin-oleanolic acid co-loaded calcium carbonate nanoparticles on hepatocellular carcinoma cells for enhanced apoptosis and reduced hepatotoxicity. Int J Nanomedicine. 2019;14:3753–3771. doi:10.2147/IJN.S19665131239661
   PubMed Web of Science ®Google Scholar
• LiuB, HanL, LiuJ, HanS, ChenZ, JiangL. Co-delivery of paclitaxel and TOS-cisplatin via TAT-targeted solid lipid nanoparticles with synergistic antitumor activity against cervical cancer. Int J Nanomed. 2017;12:955–968. doi:10.2147/IJN
   PubMed Web of Science ®Google Scholar
• QiuJ, CaiG, LiuX, MaD. α(v)β(3) integrin receptor specific peptide modified, salvianolic acid B and panax notoginsenoside loaded nanomedicine for the combination therapy of acute myocardial ischemia. Biomed Pharmacother. 2017;96:1418–1426. doi:10.1016/j.biopha.2017.10.08629079344
   PubMed Web of Science ®Google Scholar
• SongZ, ShiY, HanQ, DaiG. Endothelial growth factor receptor-targeted and reactive oxygen species-responsive lung cancer therapy by docetaxel and resveratrol encapsulated lipid-polymer hybrid nanoparticles. Biomed Pharmacother. 2018;105:18–26. doi:10.1016/j.biopha.2018.05.09529843041
   PubMed Web of Science ®Google Scholar
• WooJH, KimYH, ChoiYJ, et al. Molecular mechanisms of curcumin-induced cytotoxicity: induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl-XL and IAP, the release of cytochrome c and inhibition of Akt. Carcinogenesis. 2003;24(7):1199–1208. doi:10.1093/carcin/bgg08212807727
   PubMed Web of Science ®Google Scholar
• KongZL, KuoHP, JohnsonA, WuLC, ChangKLB. Curcumin-loaded mesoporous silica nanoparticles markedly enhanced cytotoxicity in hepatocellular carcinoma cells. Int J Mol Sci. 2019;20:12. doi:10.3390/ijms20122918
   Web of Science ®Google Scholar
• YousefS, AlsaabHO, SauS, IyerAK. Development of asialoglycoprotein receptor directed nanoparticles for selective delivery of curcumin derivative to hepatocellular carcinoma. Heliyon. 2018;4(12):e01071. doi:10.1016/j.heliyon.2018.e0107130603704
   PubMed Web of Science ®Google Scholar
• YanJ, WangY, ZhangX, LiuS, TianC, WangH. Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid-polymer hybrid nanoparticles for the enhanced anti-tumor activity in vitro and in vivo. Drug Deliv. 2016;23(5):1757–1762. doi:10.3109/10717544.2015.106942326203689
   PubMed Web of Science ®Google Scholar
• BenizriS, FereyL, AliesB, et al. Nucleoside-lipid-based nanocarriers for sorafenib delivery. Nanoscale Res Lett. 2018;13(1):17. doi:10.1186/s11671-017-2420-229327307
   PubMed Web of Science ®Google Scholar
• WangH, SunS, ZhangY, et al. Improved drug targeting to liver tumor by sorafenib-loaded folate-decorated bovine serum albumin nanoparticles. Drug Deliv. 2019;26(1):89–97. doi:10.1080/10717544.2018.156176630744448
   PubMed Web of Science ®Google Scholar
• CaoH, WangY, HeX, et al. Codelivery of sorafenib and curcumin by directed self-assembled nanoparticles enhances therapeutic effect on hepatocellular carcinoma. Mol Pharm. 2015;12(3):922–931. doi:10.1021/mp500755j25622075
   PubMed Web of Science ®Google Scholar
• ZhengN, LiuW, LiB, et al. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib. J Exp Clin Cancer Res. 2019;38(1):232. doi:10.1186/s13046-019-1216-x31151472
   PubMed Web of Science ®Google Scholar
• ZhouX, ZhangM, YungB, et al. Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma. Int J Nanomed. 2012;7:5465–5474. doi:10.2147/IJN.S33965
   PubMed Web of Science ®Google Scholar
• DuhemN, DanhierF, PourcelleV, et al. Self-assembling doxorubicin-tocopherol succinate prodrug as a new drug delivery system: synthesis, characterization, and in vitro and in vivo anticancer activity. Bioconjug Chem. 2014;25(1):72–81. doi:10.1021/bc400326y24328289
   PubMed Web of Science ®Google Scholar
• ParkC, YooJ, LeeD, JangSY, KwonS, KooH. Chlorin e6-loaded PEG-PCL nanoemulsion for photodynamic therapy and in vivo drug delivery. Int J Mol Sci. 2019;20:16. doi:10.3390/ijms20163958
   Web of Science ®Google Scholar
• ZiaQ, KhanAA, SwalehaZ, OwaisM. Self-assembled amphotericin B-loaded polyglutamic acid nanoparticles: preparation, characterization and in vitro potential against Candida albicans. Int J Nanomed. 2015;10:1769–1790. doi:10.2147/IJN.S63155
   PubMed Web of Science ®Google Scholar
• BabosG, BiróE, MeiczingerM, FeczkóT. Dual drug delivery of sorafenib and doxorubicin from PLGA and PEG-PLGA polymeric nanoparticles. Polymers (Basel). 2018;10:8. doi:10.3390/polym10080895
   Web of Science ®Google Scholar
• WangW, ChenT, XuH, et al. Curcumin-loaded solid lipid nanoparticles enhanced anticancer efficiency in breast cancer. Molecules. 2018;23:7.
   Web of Science ®Google Scholar
• ZhengG, ZhengM, YangB, FuH, LiY. Improving breast cancer therapy using doxorubicin loaded solid lipid nanoparticles: synthesis of a novel arginine-glycine-aspartic tripeptide conjugated, pH sensitive lipid and evaluation of the nanomedicine in vitro and in vivo. Biomed Pharmacother. 2019;116:109006. doi:10.1016/j.biopha.2019.10900631152925
   PubMed Web of Science ®Google Scholar
• LuoW, WenG, YangL, et al. Dual-targeted and pH-sensitive doxorubicin prodrug-microbubble complex with ultrasound for tumor treatment. Theranostics. 2017;7(2):452–465. doi:10.7150/thno.1667728255342
   PubMed Web of Science ®Google Scholar
• ZhuB, YuL, YueQ. Co-delivery of vincristine and quercetin by nanocarriers for lymphoma combination chemotherapy. Biomed Pharmacother. 2017;91:287–294. doi:10.1016/j.biopha.2017.02.11228463792
   PubMed Web of Science ®Google Scholar
• LiuL, DaiH, WuY, et al. In vitro and in vivo mechanism of hepatocellular carcinoma inhibition by β-TCP nanoparticles. Int J Nanomed. 2019;14:3491–3502. doi:10.2147/IJN.S193192
   PubMed Web of Science ®Google Scholar
• ChouTC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440–446. doi:10.1158/0008-5472.CAN-09-194720068163
   PubMed Web of Science ®Google Scholar
• YanJ, WangY, JiaY, et al. Co-delivery of docetaxel and curcumin prodrug via dual-targeted nanoparticles with synergistic antitumor activity against prostate cancer. Biomed Pharmacother. 2017;88:374–383. doi:10.1016/j.biopha.2016.12.13828122302
   PubMed Web of Science ®Google Scholar
• PangX, WangT, JiangD, MuW, ZhangB, ZhangN. Functionalized docetaxel-loaded lipid-based-nanosuspensions to enhance antitumor efficacy in vivo. Int J Nanomed. 2019;14:2543–2555. doi:10.2147/IJN.S191341
   PubMed Web of Science ®Google Scholar
• LiuX, SunY, XuS, et al. Homotypic cell membrane-cloaked biomimetic nanocarrier for the targeted chemotherapy of hepatocellular carcinoma. Theranostics. 2019;9(20):5828–5838. doi:10.7150/thno.3483731534522
   PubMed Web of Science ®Google Scholar
• XieF, RLD, WFH, et al. In vivo antitumor effect of endostatin-loaded chitosan nanoparticles combined with paclitaxel on Lewis lung carcinoma. Drug Deliv. 2017;24(1):1410–1418. doi:10.1080/10717544.2017.137893828933203
   PubMed Web of Science ®Google Scholar
• ChenD, JiangX, LiuJ, JinX, ZhangC, PingQ. In vivo evaluation of novel pH-sensitive mPEG-Hz-Chol conjugate in liposomes: pharmacokinetics, tissue distribution, efficacy assessment. Artif Cells Blood Substit Immobil Biotechnol. 2010;38(3):136–142. doi:10.3109/1073119100368548120337549
   PubMed Web of Science ®Google Scholar
• ZhangY, YangC, WangW, et al. Co-delivery of doxorubicin and curcumin by pH-sensitive prodrug nanoparticle for combination therapy of cancer. Sci Rep. 2016;6:21225. doi:10.1038/srep2122526876480
   PubMed Web of Science ®Google Scholar
• WangG, WangZ, LiC, et al. RGD peptide-modified, paclitaxel prodrug-based, dual-drugs loaded, and redox-sensitive lipid-polymer nanoparticles for the enhanced lung cancer therapy. Biomed Pharmacother. 2018;106:275–284. doi:10.1016/j.biopha.2018.06.13729966971
   PubMed Web of Science ®Google Scholar
• ZhangM, ZhouX, WangB, et al. Lactosylated gramicidin-based lipid nanoparticles (Lac-GLN) for targeted delivery of anti-miR-155 to hepatocellular carcinoma. J Control Release. 2013;168(3):251–261. doi:10.1016/j.jconrel.2013.03.02023567045
   PubMed Web of Science ®Google Scholar
• ZhangL, ZhuD, DongX, et al. Folate-modified lipid-polymer hybrid nanoparticles for targeted paclitaxel delivery. Int J Nanomed. 2015;10:2101–2114. doi:10.2147/IJN.S77667
   PubMed Web of Science ®Google Scholar
• LuG, CaoL, ZhuC, et al. Improving lung cancer treatment: hyaluronic acid-modified and glutathione-responsive amphiphilic TPGS-doxorubicin prodrug-entrapped nanoparticles. Oncol Rep. 2019;42(1):361–369. doi:10.3892/or.2019.713931059082
   PubMed Web of Science ®Google Scholar
• ShangX, LiuQ, QinT, et al. Fabrication of cRGD-modified reduction-sensitive nanocapsule via pickering emulsion route to facilitate tumor-targeted delivery. Int J Nanomed. 2019;14:3361–3373. doi:10.2147/IJN.S202063
   PubMed Web of Science ®Google Scholar
• ShaoY, LuoW, GuoQ, LiX, ZhangQ, LiJ. In vitro and in vivo effect of hyaluronic acid modified, doxorubicin and gallic acid co-delivered lipid-polymeric hybrid nano-system for leukemia therapy. Drug Des Devel Ther. 2019;13:2043–2055. doi:10.2147/DDDT.S202818
   PubMed Web of Science ®Google Scholar
• HuangH, YangDP, LiuM, et al. pH-sensitive Au-BSA-DOX-FA nanocomposites for combined CT imaging and targeted drug delivery. Int J Nanomed. 2017;12:2829–2843. doi:10.2147/IJN.S128270
   PubMed Web of Science ®Google Scholar
• RuanS, YuanM, ZhangL, et al. Tumor microenvironment sensitive doxorubicin delivery and release to glioma using angiopep-2 decorated gold nanoparticles. Biomaterials. 2015;37:425–435. doi:10.1016/j.biomaterials.2014.10.00725453970
   PubMed Web of Science ®Google Scholar
• XuG, ChenY, ShanR, WuX, ChenL. Transferrin and tocopheryl-polyethylene glycol-succinate dual ligands decorated, cisplatin loaded nano-sized system for the treatment of lung cancer. Biomed Pharmacother. 2018;99:354–362. doi:10.1016/j.biopha.2018.01.06229358128
   PubMed Web of Science ®Google Scholar
• MandalD, Kumar DashS, DasB, et al. Bio-fabricated silver nanoparticles preferentially targets gram positive depending on cell surface charge. Biomed Pharmacother. 2016;83:548–558. doi:10.1016/j.biopha.2016.07.01127449536
   PubMed Web of Science ®Google Scholar
• Nazari-VananiR, MoeziL, HeliH. In vivo evaluation of a self-nanoemulsifying drug delivery system for curcumin. Biomed Pharmacother. 2019;Volume 14:715–720. doi:10.1016/j.biopha.2017.01.102
   Web of Science ®Google Scholar
• GaoZ, LiZ, YanJ, WangP. Irinotecan and 5-fluorouracil-co-loaded, hyaluronic acid-modified layer-by-layer nanoparticles for targeted gastric carcinoma therapy. Drug Des Devel Ther. 2017;11:2595–2604. doi:10.2147/DDDT
   PubMed Web of Science ®Google Scholar
• CaiL, XuG, ShiC, GuoD, WangX, LuoJ. Telodendrimer nanocarrier for co-delivery of paclitaxel and cisplatin: a synergistic combination nanotherapy for ovarian cancer treatment. Biomaterials. 2015;37:456–468. doi:10.1016/j.biomaterials.2014.10.04425453973
   PubMed Web of Science ®Google Scholar
• YuD, LiW, ZhangY, ZhangB. Anti-tumor efficiency of paclitaxel and DNA when co-delivered by pH responsive ligand modified nanocarriers for breast cancer treatment. Biomed Pharmacother. 2016;83:1428–1435. doi:10.1016/j.biopha.2016.08.06127592131
   PubMed Web of Science ®Google Scholar
• YangF, LiA, LiuH, ZhangH. Gastric cancer combination therapy: synthesis of a hyaluronic acid and cisplatin containing lipid prodrug coloaded with sorafenib in a nanoparticulate system to exhibit enhanced anticancer efficacy and reduced toxicity. Drug Des Devel Ther. 2018;12:3321–3333. doi:10.2147/DDDT
   PubMed Web of Science ®Google Scholar